ARS Pharmaceuticals Inc
SPRY
NASDAQ
Biotechnology
$5.65
USD
-0.45 (-7.38%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $605.75M
Volume 5.0M
Revenue
$98.99M
TTM
+1.9%
YoY
Gross Margin
74%
TTM
-24.3%
YoY
Net Income
$-197.98M
TTM
-1165.0%
YoY
Operating Cash Flow
$-175.07M
TTM
-754.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 8.0 | 15.7 | 32.5 | 28.1 | 22.7 |
YoY Growth | — | +3043.4% | +1471.6% | -67.6% | +184.5% |
Cost of Revenue | 1.1 | 5.0 | 8.2 | 6.2 | 6.3 |
Gross Profit | 6.9 | 10.7 | 24.3 | 21.9 | 16.4 |
Selling, General & Administrative | 41.1 | 54.3 | 74.8 | 60.0 | 72.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 44.1 | 58.3 | 77.5 | 63.4 | 76.5 |
Operating Income | -37.2 | -47.6 | -53.2 | -41.5 | -60.1 |
EBITDA | -36.9 | -47.3 | -52.8 | -41.0 | -59.7 |
Other Income / Expense | 0.0 | 2.7 | 2.1 | -10.4 | -2.4 |
Total Other Income / Expense | 3.2 | 2.7 | 2.1 | 0.3 | -0.5 |
Income Before Income Taxes | -33.9 | -44.9 | -51.1 | -41.2 | -60.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 |
Net Income | -33.9 | -44.9 | -51.2 | -41.3 | -60.6 |
Consolidated Net Income / Loss | -33.9 | -44.9 | -51.1 | -41.1 | -60.6 |
Net Income Attributable to Common Shareholders | -33.9 | -44.9 | -51.1 | -41.1 | -60.6 |
Basic EPS | -$0.35 | -$0.46 | -$0.52 | -$0.41 | -$0.61 |
Diluted EPS | -$0.35 | -$0.46 | -$0.52 | -$0.41 | -$0.61 |
Basic Shares Outstanding | 98.1M | 98.4M | 98.8M | 99.0M | 99.3M |
Diluted Shares Outstanding | 98.1M | 98.4M | 98.8M | 99.0M | 99.3M |